JP2022512735A5 - - Google Patents
Info
- Publication number
- JP2022512735A5 JP2022512735A5 JP2021521144A JP2021521144A JP2022512735A5 JP 2022512735 A5 JP2022512735 A5 JP 2022512735A5 JP 2021521144 A JP2021521144 A JP 2021521144A JP 2021521144 A JP2021521144 A JP 2021521144A JP 2022512735 A5 JP2022512735 A5 JP 2022512735A5
- Authority
- JP
- Japan
- Prior art keywords
- wisp1
- pharmaceutical composition
- composition according
- antibody
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163238A JP2025011102A (ja) | 2018-10-19 | 2024-09-20 | 肝疾患を治療するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747903P | 2018-10-19 | 2018-10-19 | |
| US62/747,903 | 2018-10-19 | ||
| PCT/US2019/056910 WO2020081920A1 (en) | 2018-10-19 | 2019-10-18 | Compositions and methods for treatment of liver disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163238A Division JP2025011102A (ja) | 2018-10-19 | 2024-09-20 | 肝疾患を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512735A JP2022512735A (ja) | 2022-02-07 |
| JP2022512735A5 true JP2022512735A5 (https=) | 2022-10-25 |
Family
ID=70284106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521144A Withdrawn JP2022512735A (ja) | 2018-10-19 | 2019-10-18 | 肝疾患を治療するための組成物および方法 |
| JP2024163238A Pending JP2025011102A (ja) | 2018-10-19 | 2024-09-20 | 肝疾患を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163238A Pending JP2025011102A (ja) | 2018-10-19 | 2024-09-20 | 肝疾患を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210388073A1 (https=) |
| EP (1) | EP3866852A4 (https=) |
| JP (2) | JP2022512735A (https=) |
| KR (1) | KR20210081366A (https=) |
| CN (2) | CN113271971A (https=) |
| AU (1) | AU2019361120A1 (https=) |
| CA (1) | CA3117098A1 (https=) |
| IL (1) | IL282251A (https=) |
| WO (1) | WO2020081920A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020348295A1 (en) | 2019-09-16 | 2022-04-07 | Insmed Incorporated | Anti-stem cell factor antibodies and methods of use thereof |
| EP4051689A4 (en) * | 2019-11-01 | 2023-11-29 | Figene, LLC | FIBROBLAST THERAPY TO TREAT SCLEROSING CHOLANGITIS |
| CN117487010B (zh) * | 2022-08-02 | 2025-02-14 | 东莞市朋志生物科技有限公司 | 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒 |
| IL322733A (en) * | 2023-03-03 | 2025-10-01 | Karydo Therapeutix Inc | Antibody or antigen-binding fragment thereof |
| CN117045680B (zh) * | 2023-10-12 | 2023-12-08 | 北京国卫生物科技有限公司 | 促进肝脏再生的干细胞制剂及其制备方法 |
| WO2025179048A2 (en) * | 2024-02-20 | 2025-08-28 | Ecogenome Llc | Antibodies that bind dach1 and methods of use |
| CN119331100B (zh) * | 2024-10-16 | 2025-07-25 | 天津大学 | 特异性结合25-羟基维生素d的单克隆抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1027437T3 (da) * | 1997-10-29 | 2008-11-24 | Genentech Inc | Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1 |
| EP1177796B1 (en) * | 1999-04-27 | 2011-04-27 | Mitsubishi Tanabe Pharma Corporation | Medicament for prevention or therapeutic treatment of liver disease |
| EP1424391A4 (en) * | 2001-08-08 | 2004-09-08 | Ajinomoto Kk | GROUP OF GENES PARTICIPATING IN THE ACTIVATION OF LIVER ASTROCYTES |
| CA3102008A1 (en) * | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| JP2017513854A (ja) * | 2014-04-15 | 2017-06-01 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｗｉｓｐ１に結合する抗原結合タンパク質 |
| CN116059378A (zh) * | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| WO2017201422A1 (en) * | 2016-05-20 | 2017-11-23 | The General Hospital Corporation | Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases |
-
2019
- 2019-10-18 CA CA3117098A patent/CA3117098A1/en active Pending
- 2019-10-18 CN CN201980083971.8A patent/CN113271971A/zh active Pending
- 2019-10-18 AU AU2019361120A patent/AU2019361120A1/en active Pending
- 2019-10-18 CN CN202411435476.8A patent/CN120305401A/zh active Pending
- 2019-10-18 EP EP19873989.8A patent/EP3866852A4/en active Pending
- 2019-10-18 JP JP2021521144A patent/JP2022512735A/ja not_active Withdrawn
- 2019-10-18 WO PCT/US2019/056910 patent/WO2020081920A1/en not_active Ceased
- 2019-10-18 US US17/286,011 patent/US20210388073A1/en not_active Abandoned
- 2019-10-18 KR KR1020217014607A patent/KR20210081366A/ko active Pending
-
2021
- 2021-04-12 IL IL282251A patent/IL282251A/en unknown
-
2024
- 2024-09-04 US US18/824,691 patent/US20250223344A1/en active Pending
- 2024-09-20 JP JP2024163238A patent/JP2025011102A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512735A5 (https=) | ||
| US20240124874A1 (en) | C/EBP Alpha Short Activating RNA Compositions and Methods of Use | |
| Tolonen et al. | Inhibition of Let‐7 micro RNA attenuates myocardial remodeling and improves cardiac function postinfarction in mice | |
| Bonvin et al. | Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication | |
| US20200197432A1 (en) | Methods And Compositions For Controlling Cardiac Fibrosis And Remodeling | |
| JPWO2018193902A1 (ja) | マイクロｒｎａによるｂ型肝炎ウイルスに対する抗ウイルス効果 | |
| Benitez et al. | Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic‐and cholestatic‐induced liver injury | |
| Fu et al. | Delivering LINE1 antisense oligonucleotides via endothelial targeting extracellular vesicles to ameliorate myocardial infarction-induced cardiac senescence | |
| EP3395363B1 (en) | Compounds for use in treating hbv-and hcv-related conditions | |
| US10378015B2 (en) | Targeting hepatitis B virus (HBV) host factors | |
| Meng et al. | TAT peptides mediated small interfering RNA delivery to Huh-7 cells and efficiently inhibited hepatitis C virus RNA replication | |
| Kumar et al. | Endogenous antiviral microRNAs determine permissiveness for hepatitis B virus replication in cultured human fetal and adult hepatocytes | |
| Kumar et al. | Control of HBV replication by antiviral microRNAs transferred by lentiviral vectors for potential cell and gene therapy approaches | |
| WO2024126765A1 (en) | Rnai-based therapies targeting claudin-1 for the treatment and prevention of fibrotic diseases | |
| US20250163420A1 (en) | Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128 | |
| EP3873488B1 (en) | Pharmaceutical compositions for use in treating an hbv or hdv infection | |
| Zhang et al. | Targeted suppression of microRNA-33 in lesional macrophages using pH low-insertion peptides (pHLIP) improves atherosclerotic plaque regression | |
| CN121796556A (zh) | Barx1和nkx1-1在抗乙型肝炎病毒中的应用 | |
| Sato et al. | Therapeutic knockdown of MLKL reduces diet-induced obesity and improves insulin signalling in mature adipocytes | |
| Gregory | Investigating the use of oligonucleotide therapies to target tumour suppressor genes in hepatocellular carcinoma | |
| HK40070347A (en) | C/ebp alpha short activating rna compositions and methods of use | |
| JP2023108978A (ja) | ＨＢＶ由来ｃｃｃＤＮＡの抑制剤、抑制方法、ＨＢＶ感染症用医療組成物、およびＨＢＶ感染症の治療方法 | |
| HK40018320B (en) | C/ebp alpha short activating rna compositions and methods of use | |
| HK40018320A (en) | C/ebp alpha short activating rna compositions and methods of use | |
| YINGFANG | MCPIP1 reduces HBV-RNA by targeting its epsilon structure |